

Mukarba ChowK-Panipat Toll Roads Limited

September 04, 2024

Facilities/Instruments	ities/Instruments Amount (₹ crore)		Rating Action	
Long Term Bank Facilities	1,375.00	CARE D; ISSUER NOT COOPERATING*	Rating continues to remain under ISSUER NOT COOPERATING category	

Details of instruments/facilities in Annexure-1

Rationale & Key Rating Drivers

CARE Ratings Ltd. had, vide its press release dated July 10, 2023, placed the rating(s) of Mukarba ChowK-Panipat Toll Roads Limited (MCTRL) under the 'issuer non-cooperating' category as MCTRL had failed to provide information for monitoring of the rating as agreed to in its Rating Agreement. MCTRL continues to be non-cooperative despite repeated requests for submission of information through e-mails, phone calls and a letter/email dated May 25, 2024, June 04, 2024 and June 14, 2024. In line with the extant SEBI guidelines, CARE Ratings Ltd. has reviewed the rating on the basis of the best available information which however, in CARE Ratings Ltd.'s opinion is not sufficient to arrive at a fair rating.

Users of this rating (including investors, lenders and the public at large) are hence requested to exercise caution while using the above rating(s).

Analytical approach: Standalone

Outlook: Not Applicable

Detailed description of the key rating drivers:

Please refer to PR dated July 10, 2023

Applicable criteria

Definition of Default

Policy in respect of non-cooperation by issuers

About the company

MCPTRL is a special purpose vehicle (SPV) incorporated in August 2015 and a wholly owned by Essel Infraprojects Limited (EIL). EIL had been awarded the project for carrying out eight laning from existing 6/8 lane of Mukarba Chowk to Panipat section of NH 1 in the state of Haryana under National Highways Development Project (NHDP) phase IV by National Highways Authority of India under design, build, finance, operate and transfer (DBFOT) – toll basis covering a length of approximately 70 kilometres (km). Due to the inability of EIL to deliver the project within the stipulated timeline, Welspun Infrafacility Limited acquired the project vide 'harmonious substitution' in 2020 which was recommended by the project lenders and subsequently approved by National Highways Authority of India (NHAI) post termination of work given to EIL.

Brief Financials (Rs. crore)	March 31, 2022 (A)	March 31, 2023 (A)
Total operating income	0.00	0.00
PBILDT	0.00	0.00
PAT	0.00	0.00
Overall gearing (times)	0.00	0.00
Interest coverage (times)	0.00	0.00

A: Audited; Note: 'the above results are latest financial results available'

1 CARE Ratings Ltd.

^{*}Issuer did not cooperate; based on best available information

¹Complete definition of the ratings assigned are available at www.careedge.in and other CARE Ratings Ltd.'s publications



Status of non-cooperation with previous CRA: Not Applicable

Any other information: Not Applicable

Rating history for last three years: Please refer Annexure-2

Covenants of rated instrument / facility: Detailed explanation of covenants of the rated instruments/facilities is given in

Annexure-3

Complexity level of various instruments rated: Annexure-4

Lender details: Annexure-5

Annexure-1: Details of Instruments/Facilities

Name of the Instrument	ISIN	Date of Issuance (DD-MM-YYYY)	Coupon Rate (%)	Maturity Date (DD- MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned along with Rating Outlook
Fund-based - LT- Term Loan		-	-	March 2031	1375.00	CARE D; ISSUER NOT COOPERATING*

^{*}Issuer did not cooperate; based on best available information.

Annexure-2: Rating history for the last three years

	Name of the		Current Rat	ings	Rating History			
Sr. No	Name of the Instrument/Bank Facilities	Typ e	Amount Outstanding (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2024-2025	Date(s) and Rating(s) assigned in 2023-2024	Date(s) and Rating(s) assigned in 2022-2023	Date(s) and Rating(s) assigned in 2021-2022
1	Fund-based - LT-Term Loan	LT	1375.00	CARE D; ISSUER NOT COOPERATI NG*	-	1)CARE D; ISSUER NOT COOPERATIN G* (10-Jul-23)	1)CARE D; ISSUER NOT COOPERATIN G* (26-Apr-22)	-

^{*}Issuer did not cooperate; based on best available information.

LT: Long term

Annexure-3: Detailed explanation of covenants of the rated instruments/facilities: Not Applicable

Annexure-4: Complexity level of the various instruments rated

Sr. No.	Name of the Instrument	Complexity Level
1	Fund-based - LT-Term Loan	Simple

Annexure-5: Lender details

To view the lender wise details of bank facilities please click here

Note on complexity levels of the rated instrument: CARE Ratings has classified instruments rated by it on the basis of complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for any clarifications.

2 CARE Ratings Ltd.



Contact us

Media Contact

Mradul Mishra Director

CARE Ratings Limited Phone: +91-22-6754 3596

E-mail: mradul.mishra@careedge.in

Relationship Contact

Saikat Roy Senior Director

CARE Ratings Limited
Phone: +91 22 6754 3404
E-mail: saikat.roy@careedge.in

Analytical Contacts

Shachee Vyas Assistant Director **CARE Ratings Limited** Phone: +91-079-40265665

E-mail: shachee.tripathi@careedge.in

Aniket Shringarpure Lead Analyst

CARE Ratings Limited
Phone: +91-079-40265659

E-mail: aniket.shringarpure@careedge.in

Devanshi Mewada Associate Analyst CARE Ratings Limited

E-mail: devanshi.mewada@careedge.in

About us

Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India (SEBI), it has also been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates to raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages our domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments including commercial papers, corporate bonds and debentures, and structured credit.

Disclaimer:

The ratings issued by CARE Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. These ratings do not convey suitability or price for the investor. The agency does not constitute an audit on the rated entity. CARE Ratings has based its ratings/outlook based on information obtained from reliable and credible sources. CARE Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating/outlook assigned by CARE Ratings is, inter-alia, based on the capital deployed by the partners/proprietors and the current financial strength of the firm. The ratings/outlook may change in case of withdrawal of capital, or the unsecured loans brought in by the partners/proprietors in addition to the financial performance and other relevant factors. CARE Ratings is not responsible for any errors and states that it has no financial liability whatsoever to the users of the ratings of CARE Ratings of CARE Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades.

For the detailed Rationale Report and subscription information, please visit www.careedge.in

3 CARE Ratings Ltd.